| Yasmine Sadiq Wasfi, MD | |
|
3400 Spruce St, 3 Ravdin Building, Suite F, Philadelphia, PA 19104-4206 | |
| (215) 662-3202 | |
| (215) 349-8432 |
| Full Name | Yasmine Sadiq Wasfi |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 3400 Spruce St, Philadelphia, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720235898 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | MD066198L (Pennsylvania) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | MD066198L (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Yasmine Sadiq Wasfi, MD 3400 Spruce St, 3 Ravdin Building, Suite F, Philadelphia, PA 19104-4206 Ph: (215) 662-3202 | Yasmine Sadiq Wasfi, MD 3400 Spruce St, 3 Ravdin Building, Suite F, Philadelphia, PA 19104-4206 Ph: (215) 662-3202 |
News Archive
Access Scientific has received FDA clearance for The PICC WANDTM, which enables clinicians to insert a peelable sheath for PICC or Midline catheter placement using the new Accelerated Seldinger Technique (AST). The PICC WAND is an all-in-one safety introducer that addresses the over-wire vascular access market, valued at more than $1 billion, by providing faster, safer and simpler vascular access.
A combination of biochemical and MRI markers will allow improved measurement of osteoarthritis (OA) progression. The biomarkers, described in BioMed Central's open access journal Arthritis Research and Therapy, will be useful for the design and interpretation of trials of new disease modifying drugs.
Researchers from Imperial College London are looking for volunteers to test whether cannabinoids, the active ingredient of cannabis, can be used to alleviate the sensation of breathlessness caused by illnesses such as chronic obstructive pulmonary disease (COPD).
Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.
› Verified 9 days ago
Philippe Olivier Szapary, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3400 Civic Center Blvd, East Pavilion, 2nd Floor, Philadelphia, PA 19104 Phone: 215-615-4949 | |
Dr. Jamie L. Garfield, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-5864 Fax: 215-707-6867 | |
Maria Esther Escorcia De Leon, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-1622 Fax: 215-707-0943 | |
Cherag Daruwala, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2301 E Allegheny Ave, Suite 190b, Philadelphia, PA 19134 Phone: 215-926-3120 Fax: 215-926-3123 | |
Dr. Robert Burke, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 51 N 39th St, Philadelphia, PA 19104 Phone: 215-662-9436 Fax: 215-243-3208 | |
Eva Hassan Alsheik, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 219 N Broad St, 5th Floor, Philadelphia, PA 19107 Phone: 215-762-6071 | |
Dr. Jason Thomas Ackrivo, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3400 Spruce St, Philadelphia, PA 19104 Phone: 215-614-0871 |